Shunsei Hirohata1, Asami Abe2, Akira Murasawa2, Toshihisa Kanamono3, Tetsuya Tomita4, Hideki Yoshikawa4. 1. a Department of Rheumatology and Infectious Diseases , Kitasato University School of Medicine , Kanagawa , Japan. 2. b Department of Rheumatology , Niigata Rheumatic Center , Niigata , Japan. 3. c Nagano University of Health & Medicine , Nagano , Japan , and. 4. d Department of Orthopedic Surgery , Osaka University Medical School , Osaka , Japan.
Abstract
OBJECTIVE: To compare the influences of tocilizumab (TCZ) and TNF inhibitors (TNFi) on the angiogenesis in synovial tissues of rheumatoid arthritis (RA). METHODS: Synovial tissues were obtained during joint operations from 13 RA patients treated with TCZ for at least 4 months with or without previous use of TNFi, from 13 RA patients with TNFi alone and from 10 RA patients with only conventional synthetic DMARDs (csDMARDs). Synovial tissues were evaluated by hematoxylin and eosin stain as well as by immunohistological staining with anti-CD31 in which the microvessel densities (MVD) were quantitated. Synovial histopathology was scored for various components. RESULTS: The most remarkable change in the synovium with TCZ was reduced angiogenesis as well as degeneration of lining layers irrespective of the previous use of TNFi. Thus, MVD in patients treated with TCZ with or without previous TNFi were significantly decreased compared with those in patients with TNFi alone or with csDMARDs. Moreover, MVD was significantly correlated with lining layer proliferation, but not with synovial stromal proliferation or inflammatory changes. CONCLUSIONS: These results demonstrated that inhibition of angiogenesis is a unique action of TCZ. Moreover, the data also suggest that lining layers proliferation might be closely associated with angiogenesis.
OBJECTIVE: To compare the influences of tocilizumab (TCZ) and TNF inhibitors (TNFi) on the angiogenesis in synovial tissues of rheumatoid arthritis (RA). METHODS: Synovial tissues were obtained during joint operations from 13 RApatients treated with TCZ for at least 4 months with or without previous use of TNFi, from 13 RApatients with TNFi alone and from 10 RApatients with only conventional synthetic DMARDs (csDMARDs). Synovial tissues were evaluated by hematoxylin and eosin stain as well as by immunohistological staining with anti-CD31 in which the microvessel densities (MVD) were quantitated. Synovial histopathology was scored for various components. RESULTS: The most remarkable change in the synovium with TCZ was reduced angiogenesis as well as degeneration of lining layers irrespective of the previous use of TNFi. Thus, MVD in patients treated with TCZ with or without previous TNFi were significantly decreased compared with those in patients with TNFi alone or with csDMARDs. Moreover, MVD was significantly correlated with lining layer proliferation, but not with synovial stromal proliferation or inflammatory changes. CONCLUSIONS: These results demonstrated that inhibition of angiogenesis is a unique action of TCZ. Moreover, the data also suggest that lining layers proliferation might be closely associated with angiogenesis.
Authors: Fatemeh Khodadust; Aiarpi Ezdoglian; Maarten M Steinz; Judy R van Beijnum; Gerben J C Zwezerijnen; Gerrit Jansen; Sander W Tas; Conny J van der Laken Journal: Int J Mol Sci Date: 2022-06-25 Impact factor: 6.208
Authors: Amelia C Hurley-Novatny; Jules D Allbritton-King; Smita Jha; Edward W Cowen; Robert A Colbert; Fatemeh Navid; Timothy Bhattacharyya Journal: J Invest Dermatol Date: 2022-02-19 Impact factor: 7.590
Authors: Ying Wang; Yingmei Wei; Xiu Cheng; Xiaojin Sun; Linyan Ma; Yining Song; Jing Zhou; Fang Wei; Hao Liu Journal: Nan Fang Yi Ke Da Xue Xue Bao Date: 2018-07-30
Authors: Devy Zisman; Mirna Safieh; Elina Simanovich; Joy Feld; Amalia Kinarty; Liron Zisman; Tal Gazitt; Amir Haddad; Muna Elias; Itzhak Rosner; Lisa Kaly; Michal A Rahat Journal: Front Immunol Date: 2021-12-15 Impact factor: 7.561